Why Mounjaro Doesn't Work for Some People (and What to Do About It)

Is it the medicine, or is it something that can be changed?

This is the decision most people are actually trying to make. Mounjaro (tirzepatide) activates both GIP and GLP-1 receptors, reducing appetite and slowing gastric emptying. That dual mechanism produced average weight reductions of around 20–21% at the 15 mg dose in SURMOUNT-1, as published in the New England Journal of Medicine. But "average" is a statistical midpoint. Participants at the lower end of that distribution lost considerably less, and some experienced very little change at all. That is not failure, it is biology. If you are wondering whether some people simply do not lose weight on Mounjaro, the short answer is yes, and the reasons range from biological variation to addressable habits. The question worth asking is whether the reason sits in something addressable (dose, technique, food habits, an interacting medicine) or in individual physiology that simply responds less strongly. Often it is a mix of both, and teasing them apart takes honest reflection rather than guesswork.

Our prescribers at the nume clinical team (sorry, at the nume team) review this kind of stall regularly. The pattern usually fits one of the categories below.

Dose and adherence: the most common fixable reasons

Tirzepatide is titrated slowly for good reason: the starter dose (2.5 mg) exists to let your system adjust to the medicine, not to produce weight loss. Many people who feel "it's not working" are still on a low dose where therapeutic effect is limited by design. The NHS tirzepatide page explains that the dose is increased gradually under prescriber guidance, and maximum benefit generally builds across several months at the higher maintenance doses.

Beyond dose, missed injections matter more than people expect. A weekly medicine that is skipped every couple of weeks never reaches a consistent working level. Injection technique is another underrated factor: injecting into the same spot repeatedly, not rotating between the abdomen, thigh and upper arm, or not letting the skin settle between uses can all reduce absorption. A small practical fix (the kind of thing worth mentioning at a repeat review rather than waiting until the next prescription) can make a real difference.

If you are curious how others describe the experience on this medicine, the page on people on Mounjaro covers a range of real-world patterns from the clinical literature.

Biological variation: why some people respond less strongly

Even with perfect adherence and optimal dosing, some people lose less weight than the trial averages suggest. Several biological factors contribute. Hormonal differences, particularly around insulin resistance and baseline GIP receptor sensitivity, affect how strongly the medicine's dual mechanism fires. Gut microbiome composition influences how quickly food moves through the digestive system, which interacts with the gastric-emptying effect of tirzepatide. Age, sex and menopausal status all modulate the hormonal environment the medicine is working within.

There is also a phenomenon sometimes called the "set point", the weight the body actively defends through compensatory hunger signals and metabolic adaptation. Tirzepatide blunts those signals powerfully for most people, but the degree of blunting varies. If you want to understand the specific reasons why Mounjaro might not be working for you, a prescriber review covering dose, technique and personal history is usually the most productive starting point. If weight loss has genuinely plateaued at the highest tolerated dose after six months, NICE guidance (TA1026) recommends reviewing whether continuing is appropriate. That is a clinical conversation, not something to interpret in isolation, and it is the kind of conversation a prescriber is better placed to have after reviewing your full history than a forum thread.

For a broader look at the evidence base for tirzepatide, the tirzepatide overview page sets out what the clinical programme found across different populations.

Food, activity and the things Mounjaro cannot override

Tirzepatide reduces appetite substantially for most people, but it does not suspend the laws of energy balance. If calorie intake remains high (whether through habit, highly palatable processed foods that override satiety signals, or weekend patterns that undo weekday progress) the medicine has less room to work. Protein intake matters especially: adequate protein (typically 1.2–1.6 g per kg of body weight, though personal targets belong in a conversation with a dietitian) preserves muscle mass during weight loss, which in turn supports metabolic rate. People who lose muscle alongside fat tend to see slower overall results and find weight harder to maintain.

Physical activity is not a calorie-burning exercise in the traditional sense at these doses (the numbers rarely add up that way) but resistance activity preserves muscle and improves insulin sensitivity, which amplifies how well tirzepatide works at the receptor level. Even three short sessions a week before the school run matters more metabolically than people expect.

If the current approach is not producing results and you want a prescriber to look at the full picture, a free consultation through the nume treatment page is the starting point. It costs nothing to be assessed. If you are also asking whether Mounjaro simply does not work for some people, that page looks honestly at the evidence and what it means for next steps. And if Mounjaro specifically is not the right fit, including for people considering it who have a lower starting BMI or less weight to lose, the weight-loss treatment overview covers the other licensed options available.